Cancer Clinical Trials Information Platform in Hong Kong


  1. This serves merely as an information platform about cancer clinical trials operated by different institutions in Hong Kong. HKACS is not responsible for the contents, availability and operability of the trials listed.
  2. Respective institutions usually reserve all rights regarding the implementation and execution of their respective clinical trials.
  3. Patients usually need to satisfy a complex and stringent set of selection criteria before being selected/ included in certain clinical trials. Interested parties should contact respective institutions regarding further details of the trials


Cancer Site


*in alphabetical order (Last updated on 6/11/2020)


Bladder Cancer

Institution Study Title  
CUHK A Phase 2, Randomized, Open-label Study of Nivolumab or Nivolumab / BMS-986205Alone or Combined with Intravesical BCG in Participants with BCG-Unresponsive,High-Risk, Non-Muscle Invasive Bladder Cancer Click for Details
QEH, QMH A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Of Atezolizumab (Anti PD-L1 Antibody) In Combination With Gemcitabine/Carboplatin Versus Gemcitabine/Carboplatin Alone In Patients With Untreated Locally Advanced Or Metastatic Urothelial Carcinoma Who Are Ineligible For Cisplatin-Based Therapy (WO30070) Click for Details
QEH A Phase 3, Multicenter, Multinational, Randomized, Open-label, Parallel-Arm Study Of Avelumab* (MSB0010718C) Plus Best Supportive Care Versus Best Supportive Care Alone As A Maintenance Treatment In Patients With Locally Advanced Or Metastatic Urothelial Cancer Whose Disease Did Not Progress After Completion Of First-Line Platinum-Containing Chemotherapy Click for Details


For Enquiry, please contact the respective institute, HKACS is not responsible for the outcomes of the clinical trials.